Analyst Ratings For NASDAQ:OVID – Ovid Therapeutics (NASDAQ:OVID)
Today, Ladenburg Thalmann initiated coverage on NASDAQ:OVID – Ovid Therapeutics (NASDAQ:OVID) with a Buy with a price target of $27.00.
Some recent analyst ratings include
- 4/20/2018-Ladenburg Thalmann initiated coverage with a Buy rating.
- 4/1/2018-Cowen Reiterated Rating of Buy.
- 3/9/2018-Piper Jaffray initiated coverage with a Overweight rating.
- 5/30/2017-Citigroup initiated coverage with a Buy rating.
- 5/30/2017-William Blair initiated coverage with a Outperform rating.
- 5/30/2017-JMP Securities initiated coverage with a Mkt Outperform rating.
- On 8/25/2017 Jeremy M Levin, CEO, bought 15,334 with an average share price of $7.15 per share and the total transaction amounting to $109,638.10.
Recent Trading Activity for NASDAQ:OVID – Ovid Therapeutics (NASDAQ:OVID)
Shares of NASDAQ:OVID – Ovid Therapeutics closed the previous trading session at 9.97 down -0.17 1.68% with 9.800000190734863 shares trading hands.